All In Biotech

NDA 209819 · Indivior

Sublocade

Buprenorphine · Subcutaneous · Partial Opioid Agonist

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Nov 30, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

512

125 Phase 3, 43 recruiting

FAERS reports

29,342

20,423 serious, 5,267 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously. ( 5.1 ) Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. ( 5.2 ) WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY See full prescribing...

What it is approved for

From the label in effect Jul 27, 2026.

SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. SUBLOCADE contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. ( 1 ) SUBLOCADE should be used as part of a complete treatment program that includes counseling and psychosocial support. ( 1 )

Mechanism: SUBLOCADE Injection contains buprenorphine. Buprenorphine is a partial agonist at the mu- opioid receptor and an antagonist at the kappa-opioid receptor.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • SUBLOCADE · BUPRENORPHINE 100MG/0.5ML (100MG/0.5ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
  • SUBLOCADE · BUPRENORPHINE 300MG/1.5ML (200MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Buprenorphine" as an intervention, any sponsor and status, largest first.

All 512 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence4,471
  • drug withdrawal syndrome2,405
  • drug abuse2,355
  • overdose2,229
  • pain2,122
  • toxicity to various agents1,653
  • death1,645
  • drug ineffective1,606
  • nausea1,468
  • emotional distress1,255
  • vomiting1,186
  • off label use1,156

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
200534
20063
20071
20083
200930
201083
2011231
2012384
2013322
2014355
2015572
2016572
2017790
20182,159
20193,435
20202,961
20213,566
20223,860
20232,520
20242,722
20252,809
20261,927

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sublocade (Buprenorphine)

2024 spending

$50.5M

Beneficiaries

5,381

24,923 claims

Per beneficiary

$9,382

$2,329.98 per unit

View as table
YearSpending
2020$7,756,488
2021$11,842,922
2022$22,449,883
2023$37,605,330
2024$50,486,306

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,775 on PubMed

Sponsor: Indivior

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.